Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the huntingtin (HTT) gene on chromosome 4p16.3. The expansion produces a mutant huntingtin protein with an abnormally long polyglutamine tract, leading to progressive neuronal dysfunction and death, particularly in the striatum and cortex. HD is characterized by a triad of motor dysfunction (chorea), cognitive decline, and psychiatric disturbances, typically manifesting in midlife with relentless progression over 15-20 years.
Ask a research question about Huntington Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Huntington Disease
creation_date: "2026-04-07T12:00:00Z"
updated_date: "2026-05-21T04:04:17Z"
category: Mendelian
description: >-
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by
an expanded CAG trinucleotide repeat in the huntingtin (HTT) gene on chromosome 4p16.3.
The expansion produces a mutant huntingtin protein with an abnormally long polyglutamine
tract, leading to progressive neuronal dysfunction and death, particularly in the
striatum and cortex. HD is characterized by a triad of motor dysfunction (chorea),
cognitive decline, and psychiatric disturbances, typically manifesting in midlife
with relentless progression over 15-20 years.
disease_term:
preferred_term: Huntington disease
term:
id: MONDO:0007739
label: Huntington disease
parents:
- Neurodegenerative Disorders
- Trinucleotide Repeat Disorders
mappings:
mondo_mappings:
- term:
id: MONDO:0007739
label: Huntington disease
mapping_predicate: skos:exactMatch
mapping_source: ORPHA:399
mapping_justification: >-
Orphanet lists MONDO:0007739 as an exact cross-reference for the
ORPHA:399 Huntington disease record.
external_assertions:
- name: Orphanet Huntington disease structured record
source: Orphanet
assertion_type: structured_disease_record
external_id: ORPHA:399
url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399
description: >-
Orphanet records Huntington disease as ORPHA:399 and provides curated
inheritance, onset, epidemiology, gene, HPO phenotype, and external
cross-reference rows used here as structured evidence.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ORPHA:399 Huntington disease"
explanation: >-
The Orphanet structured record heading identifies ORPHA:399 as the
Huntington disease record.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "MONDO:0007739 | Exact"
explanation: >-
Orphanet maps ORPHA:399 exactly to the same MONDO disease identifier used
by this entry.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "OMIM:143100 | Exact"
explanation: >-
Orphanet lists OMIM:143100 as an exact cross-reference for Huntington
disease.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ICD-10:G10 | Exact"
explanation: >-
Orphanet lists ICD-10 G10 as an exact cross-reference for Huntington
disease.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ICD-11:8A01.10 | Exact"
explanation: >-
Orphanet lists ICD-11 8A01.10 as an exact cross-reference for Huntington
disease.
definitions:
- name: Orphanet Huntington disease definition
definition_type: CASE_DEFINITION
description: >-
Orphanet defines Huntington disease as a rare central nervous system
neurodegenerative disorder characterized by choreatic movements, psychiatric
and behavioral disturbances, and dementia.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia.
explanation: >-
Orphanet's definition supports the entry's high-level disease framing and
cardinal clinical domains.
has_subtypes:
- name: Adult-onset HD
display_name: Adult-onset Huntington Disease
description: >-
Classical form with onset typically between ages 30-50, CAG repeat length
36-55, characterized by chorea, cognitive decline, and psychiatric symptoms.
- name: Juvenile HD
display_name: Juvenile Huntington Disease (Westphal variant)
description: >-
Onset before age 20, associated with longer CAG repeat expansions (usually >60),
characterized by rigidity, bradykinesia, seizures, and more rapid progression
rather than the chorea typical of adult-onset disease.
inheritance:
- name: Autosomal Dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
penetrance: COMPLETE
description: >-
HD follows autosomal dominant inheritance with complete penetrance at 40+ CAG
repeats. Reduced penetrance occurs with 36-39 repeats. Anticipation is observed,
particularly with paternal transmission due to meiotic instability of the CAG repeat.
evidence:
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Huntington disease is a fatal, inherited, neurodegenerative disease caused
by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
polyglutamine tract in the huntingtin protein.
explanation: >-
Confirms HD is an inherited disorder caused by CAG repeat expansion in HTT.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Autosomal dominant"
explanation: >-
Orphanet's inheritance section directly states autosomal dominant
inheritance for Huntington disease.
prevalence:
- population: Western populations (USA, Canada, Europe)
percentage: 8.2-9.0 per 100,000
evidence:
- reference: PMID:34350853
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnosed prevalence is estimated to be 8.2-9.0 per 100,000 in the USA,
Canada, and the 5 included European countries and 3.5 per 100,000 in Brazil.
explanation: >-
Epidemiological model using diagnosed incidence and survival data from
eight countries estimates HD prevalence in Western populations.
- population: Worldwide (Orphanet point prevalence)
percentage: 1-9 / 100 000
notes: >-
Orphanet classifies worldwide Huntington disease point prevalence as 1-9
per 100,000.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:22692795"
explanation: >-
Orphanet's epidemiology table provides the worldwide point-prevalence
class for Huntington disease.
- population: United States (Orphanet point prevalence)
percentage: 1-9 / 100 000
notes: >-
Orphanet classifies United States Huntington disease point prevalence as
1-9 per 100,000.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "1-9 / 100 000 | United States | Point prevalence | PMID:8018043"
explanation: >-
Orphanet's epidemiology table provides a United States point-prevalence
class for Huntington disease.
progression:
- phase: Age of onset
age_range: Childhood, adolescent, adult, or elderly
notes: >-
Orphanet lists Huntington disease onset categories spanning childhood
through elderly onset.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Childhood"
explanation: >-
Orphanet includes childhood among Huntington disease onset categories.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Adolescent"
explanation: >-
Orphanet includes adolescent among Huntington disease onset categories.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Adult"
explanation: >-
Orphanet includes adult among Huntington disease onset categories.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Elderly"
explanation: >-
Orphanet includes elderly among Huntington disease onset categories.
pathophysiology:
- name: HTT CAG Repeat Expansion
conforms_to: "polyglutamine_expansion_proteotoxicity#Translated CAG / Polyglutamine Repeat Expansion"
description: >-
Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1
of the HTT gene beyond 36 repeats. The expanded repeat produces a mutant huntingtin
protein with an elongated polyglutamine tract that confers a toxic gain of function.
Repeat length inversely correlates with age of onset. Normal alleles have 6-26
repeats; intermediate alleles (27-35) can expand in offspring; 36-39 repeats show
reduced penetrance; 40+ repeats are fully penetrant.
evidence:
- reference: PMID:41130308
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Huntington's Disease (HD) became the first disease mapped to a single
chromosome and associated with mutations in the huntingtin (HTT) gene,
specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
within exon 1.
explanation: >-
Confirms the causative CAG repeat expansion in HTT exon 1.
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Huntington disease is a fatal, inherited, neurodegenerative disease caused
by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
polyglutamine tract in the huntingtin protein.
explanation: >-
Confirms the toxic polyglutamine tract from CAG expansion as the primary
molecular cause.
downstream:
- target: Mutant Huntingtin Protein Aggregation
description: >-
Expanded CAG repeat produces mutant huntingtin with toxic polyglutamine tract
that misfolds and aggregates.
- target: Somatic CAG Repeat Expansion
description: >-
Germline CAG repeat undergoes further somatic expansion in post-mitotic
striatal neurons, accelerating disease onset.
- name: Somatic CAG Repeat Expansion
description: >-
Somatic expansion of the CAG repeat in post-mitotic striatal neurons, driven by
DNA mismatch repair machinery (particularly MSH3 and FAN1), accelerates disease
progression beyond what is predicted by the inherited germline repeat length.
This mechanism is now recognized as a key determinant of onset timing and a
major therapeutic target. GWAS have identified DNA repair gene variants as the
principal genetic modifiers of HD age of onset.
biological_processes:
- preferred_term: DNA mismatch repair driving somatic expansion
term:
id: GO:0006298
label: mismatch repair
evidence:
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
genome-wide association studies have identified genetic modifiers, mostly
DNA repair genes, that significantly influence disease onset and progression.
These findings point to somatic CAG repeat expansions in affected tissues as
a key pathological mechanism.
explanation: >-
GWAS studies identify DNA repair gene modifiers influencing onset via
somatic CAG expansion.
- reference: PMID:33579859
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Validation of leads including the mismatch repair protein MSH3, and
interstrand cross-link repair protein FAN1, suggest the mechanism is driven
by somatic CAG instability, which is supported by the protective effect of
CAA substitutions in the CAG tract.
explanation: >-
Validates MSH3 and FAN1 as key mediators of somatic CAG instability.
- reference: PMID:41130308
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Somatic expansion of the CAG repeat length, beyond the inherited length, has
been associated with hastening the onset of symptoms compared to that predicted
from the germline length.
explanation: >-
Confirms somatic expansion accelerates onset beyond germline prediction.
downstream:
- target: Medium Spiny Neuron Degeneration
description: >-
Somatic expansion in striatal neurons exacerbates local protein toxicity
and accelerates neuronal death.
- name: Mutant Huntingtin Protein Aggregation
conforms_to: "polyglutamine_expansion_proteotoxicity#Misfolded Polyglutamine Protein Aggregation"
description: >-
The expanded polyglutamine tract causes mutant huntingtin to misfold and form
intracellular aggregates (inclusion bodies) in neurons. These aggregates disrupt
proteostasis, sequester essential cellular proteins including transcription factors
(CBP, Sp1, TFIID, REST/NRSF), and interfere with transcriptional regulation,
axonal transport, and synaptic function. Aberrant proteolytic cleavage by caspase-6
generates toxic N-terminal fragments that accumulate in the nucleus.
biological_processes:
- preferred_term: Protein aggregation
term:
id: GO:0070841
label: inclusion body assembly
evidence:
- reference: PMID:18992820
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Cleavage of huntingtin by caspase-6 at amino acid 586 is a crucial event
in the pathogenesis of HD. Nuclear localization of huntingtin is also an
important marker of HD and preventing or delaying its nuclear accumulation
is protective in disease models.
explanation: >-
Demonstrates caspase-6 cleavage generates toxic N-terminal fragments and
their nuclear accumulation drives pathogenesis.
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Although Huntington disease has long been viewed as a consequence of
age-dependent toxicity from mutant huntingtin, genome-wide association
studies have identified genetic modifiers, mostly DNA repair genes, that
significantly influence disease onset and progression.
explanation: >-
Confirms the established view that mutant huntingtin protein toxicity
is central to HD pathogenesis.
downstream:
- target: Medium Spiny Neuron Degeneration
description: >-
Mutant huntingtin aggregates and toxic fragments cause selective death of
striatal medium spiny neurons.
- name: Medium Spiny Neuron Degeneration
conforms_to: "polyglutamine_expansion_proteotoxicity#Selective Neuronal Dysfunction and Loss"
description: >-
GABAergic medium spiny neurons (MSNs) in the caudate nucleus and putamen are
selectively vulnerable in HD. Indirect pathway MSNs expressing enkephalin and
D2 dopamine receptors are affected earliest, followed by direct pathway MSNs.
This selective vulnerability involves excitotoxicity from corticostriatal
glutamatergic inputs, mitochondrial dysfunction, impaired BDNF signaling, and
naturally low levels of protective S421 phosphorylation in striatal neurons.
cell_types:
- preferred_term: Medium spiny neuron
term:
id: CL:1001474
label: medium spiny neuron
biological_processes:
- preferred_term: Neuronal apoptosis
term:
id: GO:0006915
label: apoptotic process
- preferred_term: Glutamate excitotoxicity
term:
id: GO:0007215
label: glutamate receptor signaling pathway
- preferred_term: Impaired BDNF trophic support
term:
id: GO:0031547
label: brain-derived neurotrophic factor receptor signaling pathway
modifier: DECREASED
evidence:
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease leads to progressive motor, cognitive and psychiatric decline,
primarily resulting from loss of medium spiny neurons in the striatum.
explanation: >-
Directly confirms MSN loss in the striatum as the primary cause of HD
clinical manifestations.
- reference: PMID:18992820
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival
signaling protein kinases Akt and SGK. Phosphorylation of huntingtin at S421
is variable in different regions of the brain with the lowest levels observed
in the striatum, which is further reduced by the mutation for Huntington
disease (HD).
explanation: >-
Explains selective striatal vulnerability through naturally low levels of
neuroprotective S421 phosphorylation in the striatum.
- reference: PMID:38427495
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
HTT loss or mutation has impacts on neuro-epithelial and striatal neurons
maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic
neurons
explanation: >-
iPSC-derived models show HTT mutation impairs striatal neuron maturation
and BDNF transport, contributing to selective vulnerability.
- name: Neuroinflammation
description: >-
Reactive microglia and astrocytes contribute to HD pathogenesis through release
of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and impaired glutamate
buffering. Microglial activation occurs early, even before symptom onset, and
correlates with disease progression. Peripheral immune dysregulation is also
observed.
cell_types:
- preferred_term: Microglia
term:
id: CL:0000129
label: microglial cell
- preferred_term: Astrocyte
term:
id: CL:0000127
label: astrocyte
biological_processes:
- preferred_term: Neuroinflammatory response
term:
id: GO:0150076
label: neuroinflammatory response
evidence:
- reference: PMID:39519337
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Activation of the immune system and glial cell-mediated neuroinflammatory
responses are early pathological features and have been found in all
neurodegenerative diseases (NDDs), including HD.
explanation: >-
Dedicated HD neuroinflammation review confirming glial-mediated
neuroinflammatory responses as early pathological features of HD.
- reference: PMID:39519337
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This review highlights the significantly elevated levels of inflammatory
proteins and cellular markers observed in various HD animal models and HD
patient tissues, emphasizing the critical roles of microglia, astrocytes,
and oligodendrocytes in mediating neuroinflammation in HD.
explanation: >-
Establishes microglia and astrocytes as key mediators of neuroinflammation
in HD with elevated inflammatory markers in patient tissues.
downstream:
- target: Medium Spiny Neuron Degeneration
description: >-
Neuroinflammatory activation contributes to progressive striatal neuronal
injury in HD.
phenotypes:
- name: Chorea
category: Clinical
frequency: VERY_FREQUENT
description: >-
Involuntary, irregular, dance-like movements that are the hallmark motor feature
of adult-onset HD. Chorea typically begins subtly and worsens over time before
giving way to rigidity and bradykinesia in advanced stages.
phenotype_term:
preferred_term: Chorea
term:
id: HP:0002072
label: Chorea
evidence:
- reference: PMID:38861215
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HD is characterized by the presence of chorea, alongside other hyperkinesia,
parkinsonism and a combination of cognitive and behavioural features.
explanation: >-
Confirms chorea alongside other hyperkinesias as a characteristic feature of HD.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002072 | Chorea | Very frequent (99-80%)"
explanation: >-
Orphanet's curated HPO annotation classifies chorea as a very frequent
Huntington disease phenotype.
- name: Cognitive Decline
category: Clinical
frequency: VERY_FREQUENT
description: >-
Progressive cognitive impairment affecting executive function, attention,
psychomotor speed, and visuospatial skills, eventually progressing to subcortical
dementia. Cognitive changes may precede motor onset by 10-15 years.
phenotype_term:
preferred_term: Progressive cognitive decline
term:
id: HP:0001268
label: Mental deterioration
evidence:
- reference: PMID:40874597
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Huntington's disease (HD) is an autosomal, progressive, dominant inherited
neurological disorder characterized by motor dysfunction, cognitive decline,
and psychiatric symptoms.
explanation: >-
Confirms cognitive decline as one of the three cardinal features of HD.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001268 | Mental deterioration | Very frequent (99-80%)"
explanation: >-
Orphanet's curated HPO annotation classifies mental deterioration as a
very frequent Huntington disease phenotype.
- name: Depression
category: Clinical
frequency: FREQUENT
description: >-
Depressive symptoms are a common psychiatric manifestation of Huntington
disease and may precede motor onset.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
evidence:
- reference: PMID:38861215
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HD is characterized by the presence of chorea, alongside other hyperkinesia,
parkinsonism and a combination of cognitive and behavioural features.
explanation: >-
Confirms behavioral features as a core component of the HD clinical triad.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000716 | Depression | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies depression as a frequent
Huntington disease phenotype.
- name: Anxiety
category: Clinical
frequency: FREQUENT
description: >-
Anxiety is a frequent psychiatric manifestation of Huntington disease.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: PMID:38861215
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HD is characterized by the presence of chorea, alongside other hyperkinesia,
parkinsonism and a combination of cognitive and behavioural features.
explanation: >-
Confirms behavioral features as a core component of the HD clinical triad.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000739 | Anxiety | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies anxiety as a frequent
Huntington disease phenotype.
- name: Agitation
category: Clinical
frequency: FREQUENT
description: >-
Agitation is a frequent behavioral manifestation in the Orphanet Huntington
disease phenotype profile.
phenotype_term:
preferred_term: Agitation
term:
id: HP:0000713
label: Agitation
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000713 | Agitation | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies agitation as a frequent
Huntington disease phenotype.
- name: Aggressive Behavior
category: Clinical
frequency: FREQUENT
description: >-
Aggressive behavior is a frequent behavioral manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Aggressive behavior
term:
id: HP:0000718
label: Aggressive behavior
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000718 | Aggressive behavior | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies aggressive behavior as a
frequent Huntington disease phenotype.
- name: Compulsive Behaviors
category: Clinical
frequency: FREQUENT
description: >-
Compulsive behaviors are frequent behavioral manifestations in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Compulsive behaviors
term:
id: HP:0000722
label: Compulsive behaviors
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000722 | Compulsive behaviors | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies compulsive behaviors as a
frequent Huntington disease phenotype.
- name: Disinhibition
category: Clinical
frequency: FREQUENT
description: >-
Disinhibition is a frequent behavioral manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Disinhibition
term:
id: HP:0000734
label: Disinhibition
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000734 | Disinhibition | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies disinhibition as a frequent
Huntington disease phenotype.
- name: Irritability
category: Clinical
frequency: FREQUENT
description: >-
Irritability is a frequent psychiatric manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000737 | Irritability | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies irritability as a frequent
Huntington disease phenotype.
- name: Hallucinations
category: Clinical
frequency: FREQUENT
description: >-
Hallucinations are a frequent psychiatric manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Hallucinations
term:
id: HP:0000738
label: Hallucinations
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000738 | Hallucinations | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies hallucinations as a frequent
Huntington disease phenotype.
- name: Apathy
category: Clinical
frequency: FREQUENT
description: >-
Apathy is a frequent neuropsychiatric manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Apathy
term:
id: HP:0000741
label: Apathy
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000741 | Apathy | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies apathy as a frequent
Huntington disease phenotype.
- name: Delusion
category: Clinical
frequency: FREQUENT
description: >-
Delusion is a frequent psychiatric manifestation in the Orphanet Huntington
disease phenotype profile.
phenotype_term:
preferred_term: Delusion
term:
id: HP:0000746
label: Delusion
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000746 | Delusion | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies delusion as a frequent
Huntington disease phenotype.
- name: Hostility
category: Clinical
frequency: FREQUENT
description: >-
Hostility is a frequent behavioral manifestation in the Orphanet Huntington
disease phenotype profile.
phenotype_term:
preferred_term: Hostility
term:
id: HP:0031473
label: Anger
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0031473 | Hostility | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies hostility as a frequent
Huntington disease phenotype.
- name: Abnormal Libido
category: Clinical
frequency: FREQUENT
description: >-
Abnormal libido is a frequent behavioral manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Abnormal libido
term:
id: HP:0031845
label: Abnormal libido
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0031845 | Abnormal libido | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies abnormal libido as a frequent
Huntington disease phenotype.
- name: Memory Impairment
category: Clinical
frequency: FREQUENT
description: >-
Memory impairment is a frequent cognitive manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002354 | Memory impairment | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies memory impairment as a
frequent Huntington disease phenotype.
- name: Bradyphrenia
category: Clinical
frequency: FREQUENT
description: >-
Bradyphrenia is a frequent cognitive manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Bradyphrenia
term:
id: HP:0031843
label: Abnormally slow thought process
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0031843 | Bradyphrenia | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies bradyphrenia as a frequent
Huntington disease phenotype.
- name: Gait Disturbance
category: Clinical
frequency: FREQUENT
description: >-
Abnormal gait is a common motor manifestation of Huntington disease,
reflecting progressive basal ganglia and motor circuit dysfunction.
phenotype_term:
preferred_term: Gait disturbance
term:
id: HP:0001288
label: Gait disturbance
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies gait disturbance as a
frequent Huntington disease phenotype.
- name: Gait Imbalance
category: Clinical
frequency: FREQUENT
description: >-
Gait imbalance is a frequent motor manifestation in the Orphanet Huntington
disease phenotype profile.
phenotype_term:
preferred_term: Gait imbalance
term:
id: HP:0002141
label: Gait imbalance
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002141 | Gait imbalance | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies gait imbalance as a frequent
Huntington disease phenotype.
- name: Clumsiness
category: Clinical
frequency: FREQUENT
description: >-
Clumsiness is a frequent motor coordination manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Clumsiness
term:
id: HP:0002312
label: Clumsiness
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002312 | Clumsiness | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies clumsiness as a frequent
Huntington disease phenotype.
- name: Poor Fine Motor Coordination
category: Clinical
frequency: FREQUENT
description: >-
Poor fine motor coordination is a frequent motor manifestation in the
Orphanet Huntington disease phenotype profile.
phenotype_term:
preferred_term: Poor fine motor coordination
term:
id: HP:0007010
label: Poor fine motor coordination
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0007010 | Poor fine motor coordination | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies poor fine motor coordination
as a frequent Huntington disease phenotype.
- name: Abnormality of Eye Movement
category: Clinical
frequency: FREQUENT
description: >-
Abnormal eye movements are frequent neurologic manifestations in the
Orphanet Huntington disease phenotype profile.
phenotype_term:
preferred_term: Abnormality of eye movement
term:
id: HP:0000496
label: Abnormality of eye movement
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies abnormality of eye movement
as a frequent Huntington disease phenotype.
- name: Staring Gaze
category: Clinical
frequency: FREQUENT
description: >-
Staring gaze is a frequent ocular-motor manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Staring gaze
term:
id: HP:0025401
label: Staring gaze
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0025401 | Staring gaze | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies staring gaze as a frequent
Huntington disease phenotype.
- name: Bradykinesia
category: Clinical
frequency: FREQUENT
description: >-
Slowness of movement can accompany or follow hyperkinetic features,
especially in juvenile-onset or later-stage Huntington disease.
phenotype_term:
preferred_term: Bradykinesia
term:
id: HP:0002067
label: Bradykinesia
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002067 | Bradykinesia | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies bradykinesia as a frequent
Huntington disease phenotype.
- name: Hypokinesia
category: Clinical
frequency: FREQUENT
description: >-
Hypokinesia is a frequent hypokinetic motor manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Hypokinesia
term:
id: HP:0002375
label: Hypokinesia
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002375 | Hypokinesia | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies hypokinesia as a frequent
Huntington disease phenotype.
- name: Hyperreflexia
category: Clinical
frequency: VERY_FREQUENT
description: >-
Increased deep tendon reflexes are included in Orphanet's very frequent HPO
phenotype annotations for Huntington disease.
phenotype_term:
preferred_term: Hyperreflexia
term:
id: HP:0001347
label: Hyperreflexia
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
explanation: >-
Orphanet's curated HPO annotation classifies hyperreflexia as a very
frequent Huntington disease phenotype.
- name: Dystonia
category: Clinical
frequency: FREQUENT
description: >-
Sustained muscle contractions causing abnormal postures, particularly prominent
in juvenile-onset HD and in later stages of adult-onset disease.
phenotype_term:
preferred_term: Dystonia
term:
id: HP:0001332
label: Dystonia
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001332 | Dystonia | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies dystonia as a frequent
Huntington disease phenotype.
- name: Myoclonus
category: Clinical
frequency: FREQUENT
description: >-
Myoclonus is a frequent motor manifestation in the Orphanet Huntington
disease phenotype profile.
phenotype_term:
preferred_term: Myoclonus
term:
id: HP:0001336
label: Myoclonus
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001336 | Myoclonus | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies myoclonus as a frequent
Huntington disease phenotype.
- name: Involuntary Movements
category: Clinical
frequency: FREQUENT
description: >-
Involuntary movements are a frequent motor manifestation in the Orphanet
Huntington disease phenotype profile.
phenotype_term:
preferred_term: Involuntary movements
term:
id: HP:0004305
label: Involuntary movements
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0004305 | Involuntary movements | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies involuntary movements as a
frequent Huntington disease phenotype.
- name: Weight Loss
category: Clinical
frequency: FREQUENT
description: >-
Progressive involuntary weight loss despite adequate caloric intake, related to
hypermetabolic state from chorea, dysphagia, and central hypothalamic dysfunction.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001824 | Weight loss | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies weight loss as a frequent
Huntington disease phenotype.
- name: Generalized Muscle Weakness
category: Clinical
frequency: FREQUENT
description: >-
Generalized muscle weakness is a frequent motor manifestation in the
Orphanet Huntington disease phenotype profile.
phenotype_term:
preferred_term: Generalized muscle weakness
term:
id: HP:0003324
label: Generalized muscle weakness
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0003324 | Generalized muscle weakness | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies generalized muscle weakness
as a frequent Huntington disease phenotype.
- name: Abnormality of the Sense of Smell
category: Clinical
frequency: FREQUENT
description: >-
Abnormality of the sense of smell is a frequent sensory manifestation in the
Orphanet Huntington disease phenotype profile.
phenotype_term:
preferred_term: Abnormality of the sense of smell
term:
id: HP:0004408
label: Abnormality of the sense of smell
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0004408 | Abnormality of the sense of smell | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies abnormality of the sense of
smell as a frequent Huntington disease phenotype.
- name: Speech Articulation Difficulties
category: Clinical
frequency: FREQUENT
description: >-
Progressive speech difficulty due to impaired motor control of muscles
involved in speech production.
phenotype_term:
preferred_term: Speech articulation difficulties
term:
id: HP:0009088
label: Speech articulation difficulties
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0009088 | Speech articulation difficulties | Frequent (79-30%)"
explanation: >-
Orphanet's curated HPO annotation classifies speech articulation
difficulties as a frequent Huntington disease phenotype.
- name: Oral-pharyngeal Dysphagia
category: Clinical
frequency: OCCASIONAL
description: >-
Difficulty swallowing that increases aspiration risk. Aspiration pneumonia is a
leading cause of death in HD.
phenotype_term:
preferred_term: Oral-pharyngeal dysphagia
term:
id: HP:0200136
label: Oral-pharyngeal dysphagia
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0200136 | Oral-pharyngeal dysphagia | Occasional (29-5%)"
explanation: >-
Orphanet's curated HPO annotation classifies oral-pharyngeal dysphagia as
an occasional Huntington disease phenotype.
- name: Seizures
category: Clinical
subtype: Juvenile HD
description: >-
Seizures occur in approximately 25-40% of juvenile-onset HD patients
but are uncommon in adult-onset disease.
phenotype_term:
preferred_term: Seizures
term:
id: HP:0001250
label: Seizure
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: PARTIAL
evidence_source: OTHER
snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
explanation: >-
Orphanet records seizures as a frequent disease-level HPO annotation. This
partially supports the seizure phenotype here, while this entry retains the
juvenile-HD subtype context for clinical specificity.
- name: Sleep Disturbances
category: Clinical
description: >-
Sleep disturbances are prevalent in HD, including periodic limb movements (35%),
poor sleep quality (59%), excessive daytime sleepiness, and circadian rhythm
disruption. Sleep medication use is reported in 29% of patients.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
evidence:
- reference: PMID:41722529
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Meta-analysed prevalence of objectively-measured sleep disturbances include:
35% for periodic limb movements (PLM index>15/hour), 3% for REM sleep
behaviour disorder, 5% for REM sleep without atonia, and 9% for
sleep-disordered breathing (AHI>5/hour); and of self-reported measures: 29%
for use of sleep medications, 59% for poor sleep quality (Pittsburgh sleep
quality index), and 15% for excessive daytime sleepiness (Epworth sleepiness
scale).
explanation: >-
Systematic review with meta-analysis quantifying the prevalence of multiple
sleep disturbances in HD patients.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: PARTIAL
evidence_source: OTHER
snippet: "HP:0100785 | Insomnia | Occasional (29-5%)"
explanation: >-
Orphanet's insomnia annotation supports one component of the broader sleep
disturbance phenotype.
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: PARTIAL
evidence_source: OTHER
snippet: "HP:0001262 | Excessive daytime somnolence | Occasional (29-5%)"
explanation: >-
Orphanet's excessive daytime somnolence annotation supports another
component of the broader sleep disturbance phenotype.
biochemical:
- name: Neurofilament Light Chain (NfL)
notes: >-
Plasma and CSF neurofilament light chain is elevated in both pre-manifest
and manifest HD. NfL meets evidentiary guidelines as a prognostic biomarker
in premanifest HD and can detect changes in very early disease stages.
evidence:
- reference: PMID:41081429
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Evidence for neurofilament light (NfL) is sufficient to meet evidentiary
guidelines as a prognostic biomarker in preHD (ie, before clinical motor
diagnosis).
explanation: >-
Systematic review with meta-analysis establishes NfL as a validated
prognostic biomarker in pre-manifest HD.
- reference: PMID:39891767
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
sNfL levels differed significantly between preHD and early HD, and HC
(all p values < 0.05)
explanation: >-
Confirms serum NfL can distinguish pre-manifest and early HD from
healthy controls.
- name: Mutant Huntingtin Protein (mHTT)
notes: >-
Mutant huntingtin protein is quantifiable in cerebrospinal fluid and serves
as a pharmacodynamic biomarker for HTT-lowering therapies.
evidence:
- reference: PMID:38861215
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The possibility of quantifying mHTT in CSF, along with the development
of an integrated biological staging system in HD are important innovations
applicable to clinical trial design that enhance the drug development process.
explanation: >-
Highlights CSF mHTT quantification as a key innovation for HD clinical
trial design.
genetic:
- name: HTT
association: Causative
gene_term:
preferred_term: HTT
term:
id: hgnc:4851
label: HTT
notes: >-
The huntingtin gene on chromosome 4p16.3. CAG repeat expansion in exon 1
beyond 36 repeats causes HD with full penetrance at 40+ repeats (reduced
penetrance at 36-39). Normal alleles have 6-26 repeats; intermediate alleles
(27-35) can expand to pathogenic range in offspring. The gene encodes huntingtin,
a 3,144 amino acid scaffolding protein involved in vesicular transport,
transcription, autophagy, and cell survival.
evidence:
- reference: PMID:41130308
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Huntington's Disease (HD) became the first disease mapped to a single
chromosome and associated with mutations in the huntingtin (HTT) gene,
specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
within exon 1.
explanation: >-
Confirms the CAG repeat expansion in HTT exon 1 as the causative mutation.
- reference: CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z
reference_title: "HTT / Huntington disease (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HTT | HGNC:4851 | Huntington disease | MONDO:0007739 | AD | Definitive"
explanation: ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: MSH3
association: Modifier
gene_term:
preferred_term: MSH3
term:
id: hgnc:7326
label: MSH3
notes: >-
DNA mismatch repair gene identified as a key genetic modifier of HD onset age
through GWAS. MSH3 drives somatic CAG repeat expansion in striatal neurons;
variants that reduce MSH3 activity delay onset. A major therapeutic target.
evidence:
- reference: PMID:33579859
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Validation of leads including the mismatch repair protein MSH3, and
interstrand cross-link repair protein FAN1, suggest the mechanism is driven
by somatic CAG instability, which is supported by the protective effect of
CAA substitutions in the CAG tract.
explanation: >-
Identifies MSH3 as a validated modifier driving somatic CAG instability.
- name: FAN1
association: Modifier
gene_term:
preferred_term: FAN1
term:
id: hgnc:29170
label: FAN1
notes: >-
Fanconi anemia-associated nuclease 1. FAN1 protects against somatic CAG expansion;
variants that enhance FAN1 activity are associated with delayed onset of HD.
evidence:
- reference: PMID:33579859
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Validation of leads including the mismatch repair protein MSH3, and
interstrand cross-link repair protein FAN1, suggest the mechanism is driven
by somatic CAG instability, which is supported by the protective effect of
CAA substitutions in the CAG tract.
explanation: >-
Identifies FAN1 as a protective modifier against somatic CAG expansion.
- name: SLC2A3
association: Modifier
gene_term:
preferred_term: SLC2A3
term:
id: hgnc:11007
label: SLC2A3
notes: >-
Orphanet lists SLC2A3 as a modifying germline mutation association for
Huntington disease.
evidence:
- reference: ORPHA:399
reference_title: "Huntington disease (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "SLC2A3 | solute carrier family 2 member 3 | hgnc:11007 | Modifying germline mutation in"
explanation: >-
Orphanet's gene table lists SLC2A3 as a modifying germline mutation
association for Huntington disease.
treatments:
- name: Tetrabenazine
description: >-
Vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment
of chorea in HD. Reduces dopamine signaling in the basal ganglia. Most effective
of the three VMAT2 inhibitors for chorea control but associated with higher rates
of sedation and carries a boxed warning for depression.
treatment_term:
preferred_term: Tetrabenazine for chorea
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:41069601
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study suggests that three VMAT2 inhibitors are effective in ameliorating
chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
most effective in controlling chorea, whereas valbenazine may be the optimal
choice for patients with comorbid psychiatric symptoms.
explanation: >-
Network meta-analysis confirms tetrabenazine as the most effective VMAT2
inhibitor for chorea symptom control.
- name: Deutetrabenazine
description: >-
Deuterated form of tetrabenazine with improved pharmacokinetics and tolerability
profile, approved for HD chorea. Twice-daily dosing with less CYP2D6 interaction
and lower sedation risk than tetrabenazine.
treatment_term:
preferred_term: Deutetrabenazine for chorea
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:41069601
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study suggests that three VMAT2 inhibitors are effective in ameliorating
chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
most effective in controlling chorea, whereas valbenazine may be the optimal
choice for patients with comorbid psychiatric symptoms.
explanation: >-
Network meta-analysis confirms deutetrabenazine efficacy for HD chorea.
- name: Valbenazine
description: >-
Selective VMAT2 inhibitor approved in 2023 for HD chorea. Once-daily dosing
with minimal CYP2D6 interaction. May be optimal for patients with comorbid
psychiatric symptoms. Available in sprinkle formulation for patients with dysphagia.
treatment_term:
preferred_term: Valbenazine for chorea
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:41069601
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study suggests that three VMAT2 inhibitors are effective in ameliorating
chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
most effective in controlling chorea, whereas valbenazine may be the optimal
choice for patients with comorbid psychiatric symptoms.
explanation: >-
Network meta-analysis identifies valbenazine as optimal for patients with
comorbid psychiatric symptoms.
- name: HTT-Lowering Therapies
description: >-
Emerging disease-modifying approaches including antisense oligonucleotides (ASOs),
splice modulators, and microRNA-based gene therapy targeting mutant huntingtin
protein reduction. Allele-selective approaches that spare wild-type HTT are
preferred after the tominersen trial showed non-selective lowering can cause harm.
treatment_term:
preferred_term: HTT-lowering gene therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:38861215
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HD is living in an era of target-specific drug development with emphasis on
the mechanisms related to mutant Huntingtin (HTT) protein. Examples include
antisense oligonucleotides (ASO), splicing modifiers and microRNA molecules
that aim to reduce the levels of mutant HTT protein.
explanation: >-
Reviews the current landscape of HTT-lowering therapeutic approaches.
- reference: PMID:41090742
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among emerging and novel treatments for central nervous system (CNS)
disorders, gene therapy (GT), particularly using adeno-associated virus
(AAV)-mediated gene delivery, holds great promise.
explanation: >-
Reviews AAV-mediated gene therapy as a promising approach for HD treatment.
- name: Somatic Expansion Inhibition
description: >-
Novel therapeutic paradigm targeting DNA mismatch repair machinery (particularly
MSH3) to slow or halt somatic CAG repeat expansion in striatal neurons. Considered
the most promising emerging strategy as it addresses the upstream DNA-level
mechanism rather than downstream protein toxicity.
treatment_term:
preferred_term: Somatic expansion inhibitor therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:41233526
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
interventions to limit somatic repeat expansion might be effective across
multiple repeat expansion diseases and, when combined with disease-specific
approaches, such as huntingtin lowering in Huntington disease, might offer
more effective and longer-lasting clinical benefits than either strategy in
isolation.
explanation: >-
Supports somatic expansion inhibition as a promising combinatorial therapeutic
strategy for HD and other repeat expansion disorders.
- name: Genetic Counseling
description: >-
Predictive genetic testing and counseling for at-risk family members. Pre-symptomatic
testing follows international guidelines (HDSA/IHA/WFN) requiring pre- and post-test
counseling. Only 5-20% of at-risk individuals choose predictive testing.
Reproductive options include PGT-M, prenatal testing, and exclusion testing.
treatment_term:
preferred_term: Genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
- name: Supportive Care
description: >-
Multidisciplinary care including physical therapy (gait training, fall prevention),
speech therapy (dysarthria and dysphagia management), occupational therapy,
nutritional support (high-calorie diets, PEG tube in advanced stages), and
psychiatric management (SSRIs, SNRIs for depression; antipsychotics for psychosis).
treatment_term:
preferred_term: Supportive care
term:
id: MAXO:0000950
label: supportive care
discussions:
- discussion_id: gap_hd_somatic_expansion_threshold_rescue
prompt: >-
Is somatic HTT CAG expansion past a repeat-length threshold a causal,
cell-autonomous trigger for medium spiny neuron degeneration, and can
MSH3/FAN1-pathway modulation shift neurons below that threshold without
unacceptable DNA-repair toxicity?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Somatic CAG Repeat Expansion
- pathophysiology#Medium Spiny Neuron Degeneration
- pathophysiology#Mutant Huntingtin Protein Aggregation
rationale: >-
Human single-cell data now argue for a long silent phase of somatic repeat
growth followed by a high-repeat toxicity threshold. A standardized
isogenic striatal-neuron experiment would separate repeat-length threshold,
mutant huntingtin proteostasis, and DNA-repair perturbation effects before
treating somatic-expansion inhibition as a general disease-modifying
strategy.
proposed_experiments:
- experiment_id: exp_hd_isogenic_spn_repeat_threshold_modulation
name: Isogenic hPSC striatal-neuron somatic-expansion threshold assay
description: >-
Generate isogenic hPSC-derived striatal projection neuron cultures with
defined HTT CAG lengths; induce or monitor somatic expansion over
maturation; perturb MSH3 and FAN1 pathway activity; then pair single-cell
repeat sizing with neuronal identity, stress, survival, and mutant
huntingtin aggregation readouts.
experiment_type:
preferred_term: isogenic stem-cell perturbation experiment
model_systems:
- name: Isogenic hPSC-derived striatal projection neuron model
description: >-
Human pluripotent-stem-cell-derived striatal neuron system carrying
controlled HTT CAG tracts so repeat-length distributions can be linked
to cell-state and degeneration readouts in the same cells.
experimental_model_type: IPSC_DERIVED_MODEL
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
tissue_term:
preferred_term: striatum
cell_types:
- preferred_term: medium spiny neuron
cell_source: isogenic hPSC-derived neurons with engineered HTT CAG tracts
culture_system: long-maturation striatal neuron culture or striatal organoid slice
perturbations:
- name: HTT CAG tract length series
target: pathophysiology#HTT CAG Repeat Expansion
description: >-
Isogenic allelic series spanning reduced-penetrance, typical adult-onset,
and high-repeat HTT CAG lengths.
gene:
preferred_term: HTT
term:
id: hgnc:4851
label: HTT
- name: MSH3 suppression
target: pathophysiology#Somatic CAG Repeat Expansion
description: >-
Genetic or pharmacologic reduction of mismatch-repair activity predicted
to slow somatic CAG expansion.
gene:
preferred_term: MSH3
- name: FAN1 enhancement
target: pathophysiology#Somatic CAG Repeat Expansion
description: >-
FAN1-pathway enhancement to test whether repeat-stabilizing activity
can preserve neuronal identity without broad DNA-repair toxicity.
gene:
preferred_term: FAN1
readouts:
- name: Single-cell HTT CAG repeat-length distribution
target: pathophysiology#Somatic CAG Repeat Expansion
description: Repeat length measured in the same cells used for transcriptomic state assignment.
assays:
- preferred_term: single-cell repeat-length sequencing
- preferred_term: long-read sequencing
direction: POSITIVE
- name: Medium spiny neuron identity and survival
target: pathophysiology#Medium Spiny Neuron Degeneration
description: >-
Loss of striatal neuron markers, stress-state induction, and cell-loss
readouts interpreted against CAG threshold crossing.
assays:
- preferred_term: single-cell transcriptomic profiling
- preferred_term: cell viability assay
direction: POSITIVE
- name: Mutant huntingtin aggregation burden
target: pathophysiology#Mutant Huntingtin Protein Aggregation
description: Aggregation or nuclear-inclusion readout paired to repeat length.
assays:
- preferred_term: immunofluorescence assay
direction: POSITIVE
controls:
- name: Isogenic non-expanded HTT neurons
description: Matched striatal neurons carrying nonpathogenic HTT CAG length.
- name: Sham-edited expanded HTT neurons
description: Expanded-CAG neurons receiving editing or delivery controls only.
decision_criterion: >-
The threshold model is supported if neurons crossing a prespecified high
somatic-repeat range lose striatal identity and viability, and if MSH3
suppression or FAN1 enhancement reduces both threshold crossing and
degeneration without broad DNA-damage readouts.
would_support:
- pathophysiology#Somatic CAG Repeat Expansion
- pathophysiology#Medium Spiny Neuron Degeneration
would_refute:
- pathophysiology#Somatic CAG Repeat Expansion
evidence:
- reference: PMID:39824182
reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect"
explanation: >-
Establishes the threshold-like causal question by separating lower
somatic expansion from the larger expansions linked to neuronal collapse.
- reference: PMID:39824182
reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously"
explanation: >-
Supports testing whether repeat-stabilizing perturbations can prevent
the high-repeat state in a controlled human neuronal model.
- reference: PMID:33579859
reference_title: "Genetic modifiers of Huntington disease differentially influence motor and cognitive domains."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Validation of leads including the mismatch repair protein MSH3, and
interstrand cross-link repair protein FAN1, suggest the mechanism is driven
by somatic CAG instability
explanation: >-
Provides the genetic-modifier rationale for MSH3 and FAN1 perturbations.
datasets:
Huntington Disease (HD) is a devastating, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion (≥36 repeats; full penetrance ≥40) in exon 1 of the huntingtin gene (HTT) on chromosome 4p16.3. The expanded polyglutamine tract in the huntingtin protein — a 3,144 amino acid multifunctional scaffold essential for vesicular transport, transcription, autophagy, and neuronal survival — causes misfolding, aggregation, and toxic gain-of-function, preferentially destroying GABAergic medium spiny neurons (MSNs) in the striatum through eight converging pathogenic mechanisms. HD manifests as a clinical triad of progressive motor dysfunction (chorea evolving to rigidity), cognitive decline progressing to dementia, and psychiatric disturbances, with detectable premanifest changes beginning 15-20 years before motor onset. With a prevalence of approximately 5-7 per 100,000 in Western populations (~30,000 affected in the US), HD remains without disease-modifying therapy, though three VMAT2 inhibitors provide symptomatic chorea relief. The therapeutic landscape is undergoing a paradigm shift following the tominersen trial failure, with the most promising emerging strategies being somatic CAG expansion inhibitors (targeting MSH3/FAN1), allele-selective HTT lowering, and AAV-mediated gene therapy, supported by HD's uniquely organized global research infrastructure.
This report covers 21 sections: genetics, disease identifiers, epidemiology, huntingtin protein biology, molecular pathogenesis, neuropathology, clinical features, premanifest phase, differential diagnosis, diagnosis, current treatment, therapeutic pipeline, animal models, emerging concepts, genetic counseling, psychosocial impact, intermediate alleles, treatment comparison, clinical trial lessons, research infrastructure, and future directions.
| Category | CAG Length | Clinical Significance |
|---|---|---|
| Normal | 6–26 | No risk of HD; stable across generations |
| Intermediate (mutable normal) | 27–35 | No HD risk, but may expand in offspring (especially paternal transmission) |
| Reduced penetrance | 36–39 | Some individuals develop HD; incomplete penetrance |
| Full penetrance | ≥40 | Will develop HD if normal lifespan |
| Juvenile onset | ≥60 | Onset typically before age 20; more rigid/akinetic phenotype |
The CAG repeat length is inversely correlated with age of motor onset and accounts for approximately 50–70% of the variance in onset age. However, the remaining variance is influenced by:
HD shows genetic anticipation, particularly with paternal transmission. The CAG repeat is unstable during spermatogenesis, leading to potential intergenerational expansions. This explains why juvenile HD cases are more commonly paternally inherited.
| Database | Identifier |
|---|---|
| OMIM | 143100 |
| MONDO | MONDO:0007739 |
| Orphanet | ORPHA:399 |
| MeSH | D006816 |
| ICD-10 | G10 |
| DOID | DOID:12858 |
| Population | Prevalence per 100,000 |
|---|---|
| North America (Caucasian) | ~7.33 |
| Western Europe | ~5.70 |
| Australia | ~5.63 |
| Finland | ~2.12 |
| South America | ~1.57 |
| Japan | ~0.72 |
| East Asia | ~0.40 |
| Sub-Saharan Africa | ~0.02 |
The marked ethnic/geographic variation in prevalence correlates with the distribution of intermediate and high-normal CAG alleles. Western European populations have a higher proportion of alleles near the pathogenic threshold, providing a reservoir for new mutations through intergenerational expansion.
Huntingtin is a large (3,144 amino acids, ~348 kDa) scaffold protein containing: - Polyglutamine (polyQ) tract: Encoded by the CAG repeat in exon 1; normally 6-26 Qs - Proline-rich domain (PRD): Adjacent to polyQ; modulates aggregation propensity - HEAT repeats: Four clusters of α-helical repeat domains forming a solenoid structure; mediate protein-protein interactions - Subcellular localization: Nucleus, cytoplasm, axons, dendrites, perikaryon, and associated with vesicles and organelles
| Function | Mechanism | Relevance to HD |
|---|---|---|
| Vesicular transport | Scaffold for dynein/kinesin motors on microtubules | mHTT impairs BDNF transport cortex→striatum |
| Transcription regulation | Interacts with REST/NRSF, CBP, Sp1, TFIID | mHTT sequesters transcription factors → gene silencing |
| Autophagy | Scaffold for autophagy initiation and cargo recognition | mHTT aggregates overwhelm and impair autophagy |
| Anti-apoptotic signaling | Sequesters caspase-3; blocks pro-apoptotic HIP-1 | Loss of function removes survival signaling |
| Embryonic development | Essential for gastrulation | HTT knockout is embryonic lethal (E7.5) |
| Synaptic function | Vesicle recycling and neurotransmitter release | Synaptic dysfunction is an early HD feature |
| Modification | Site | Function | HD Relevance |
|---|---|---|---|
| Phosphorylation | S421 (Akt/SGK) | Neuroprotective; promotes BDNF transport | Lowest in striatum → vulnerability factor (PMID: 18992820) |
| Phosphorylation | S13/S16 | Regulates mHTT clearance | Phospho-mimetic reduces toxicity |
| Acetylation | K444 | Promotes autophagic clearance | Impaired acetylation → mHTT accumulation |
| Caspase cleavage | D513, D552, D586 | Generates N-terminal fragments | Fragments with expanded polyQ are highly toxic |
| Palmitoylation | C214 (HIP14-mediated) | Membrane targeting/trafficking | Reduced in HD → altered protein trafficking |
| SUMOylation | K6, K9, K15 | Competes with ubiquitination | Alters aggregation and clearance dynamics |
Key Insight: The finding that S421 phosphorylation is naturally lowest in striatal neurons provides a molecular explanation for selective vulnerability — these neurons have the least protective modification of HTT, making them most susceptible to mHTT toxicity.
Wikidata pathway analysis reveals HTT participates in multiple critical signaling cascades: MAPK, Wnt, insulin, TGF-beta, VEGF, apoptosis, PDGF, p38 MAPK, ErbB, toll-like receptor, and inflammatory (IL-1, IL-6, TNF-alpha) pathways. This broad involvement explains why mHTT disruption has such pleiotropic effects.
The expanded polyglutamine (polyQ) tract causes huntingtin to: 1. Misfold and aggregate → forms intranuclear inclusions and cytoplasmic aggregates 2. Sequester essential proteins → disrupts proteostasis, transcription, and transport 3. Undergo aberrant proteolytic cleavage → generates toxic N-terminal fragments
Medium spiny neurons (MSNs) in the caudate nucleus and putamen are preferentially affected due to: - High excitatory glutamatergic input from cortex - Dependence on BDNF from cortical projections - High metabolic demand and vulnerability to energy deficits - Greater somatic CAG expansion in striatal vs. other brain regions - Expression pattern of DNA repair enzymes promoting instability
The indirect pathway MSNs (D2 receptor-expressing, enkephalin-positive) are affected earliest, followed by direct pathway MSNs (D1 receptor-expressing, substance P-positive), correlating with the clinical progression from chorea to rigidity.
| Grade | Pathological Features |
|---|---|
| Grade 0 | No gross atrophy; microscopic neuronal loss in caudate head |
| Grade 1 | Mild caudate atrophy; up to 50% neuronal loss in caudate |
| Grade 2 | Moderate caudate atrophy; striatal atrophy visible grossly |
| Grade 3 | Severe striatal atrophy; marked neuronal loss with astrogliosis |
| Grade 4 | Very severe atrophy; >95% neuronal loss in caudate; cortical atrophy |
| Stage | TFC Score | Duration | Key Features |
|---|---|---|---|
| I | 11–13 | ~8 years | Subtle motor/cognitive changes; fully functional |
| II | 7–10 | ~3 years | Chorea more evident; reduced work capacity |
| III | 3–6 | ~3 years | Cannot work; needs assistance with finances |
| IV | 1–2 | ~3 years | Requires substantial assistance with daily living |
| V | 0 | Variable | Total dependence; nursing care required |
Mean age of motor onset: ~45 years (range: childhood to >70 years) Mean disease duration: 15–20 years from motor onset to death Cause of death: Most commonly aspiration pneumonia, followed by cardiovascular disease and suicide
HD is unique among neurodegenerative diseases in that gene-positive individuals can be identified decades before clinical onset, enabling detailed characterization of the premanifest phase.
| Years Before Motor Onset | Change Detectable |
|---|---|
| ~20 years | Plasma NfL begins to rise above controls |
| ~15-20 years | Subtle striatal (caudate) atrophy on volumetric MRI |
| ~10-15 years | Executive dysfunction and processing speed deficits detectable on neuropsychological testing |
| ~5-10 years | Psychiatric symptoms (depression, irritability, anxiety) may appear |
| ~2-5 years | Subtle motor signs (oculomotor abnormalities, finger tapping irregularities) |
| 0 years | Clinical motor diagnosis (UHDRS Diagnostic Confidence Level 4) |
The extended premanifest phase, combined with genetic predictability and measurable biomarkers (NfL, volumetric MRI), makes HD uniquely suited for preventive clinical trials. Intervening before irreversible neuronal loss could maximize therapeutic benefit. Current trials (e.g., HD-DCI) are enrolling premanifest carriers based on biomarker-predicted proximity to onset.
Approximately 2-40% of patients presenting with an HD-like phenotype test negative for HTT CAG expansion (PMID: 41612618). Key phenocopies include:
| Condition | Gene/Mutation | Inheritance | Distinguishing Features |
|---|---|---|---|
| HDL1 | PRNP octapeptide repeat insertion | AD | Personality changes, seizures; prion disease |
| HDL2 | JPH3 CTG/CAG expansion | AD | Virtually indistinguishable from HD; common in African ancestry |
| SCA17 | TBP CAG expansion | AD | Prominent ataxia alongside chorea and dementia |
| C9orf72 | GGGGCC repeat expansion | AD | FTD/ALS spectrum features; increasingly recognized HD phenocopy |
| Chorea-acanthocytosis | VPS13A mutations | AR | Lip/tongue biting, acanthocytes on blood smear |
| McLeod syndrome | XK gene mutations | X-linked | Acanthocytes, cardiomyopathy, elevated CK |
| DRPLA | ATN1 CAG expansion | AD | Epilepsy, ataxia; more common in Japan |
| Benign hereditary chorea | NKX2-1 (TITF1) mutations | AD | Non-progressive; thyroid/lung involvement |
| Condition | Key Diagnostic Features |
|---|---|
| Sydenham chorea | Post-streptococcal; children; anti-basal ganglia antibodies |
| SLE/antiphospholipid syndrome | Young women; anti-phospholipid antibodies |
| Tardive dyskinesia | History of dopamine receptor blocker exposure |
| Wilson disease | Kayser-Fleischer rings; low ceruloplasmin; liver disease |
| Anti-NMDAR encephalitis | Young women; psychiatric onset; ovarian teratoma |
| Polycythemia vera | Elderly; elevated hematocrit |
| Thyrotoxicosis | Thyroid function abnormalities; reversible |
For patients presenting with chorea ± cognitive/psychiatric features: 1. First-line: HTT CAG repeat testing (definitive for HD) 2. If HTT-negative: Blood smear (acanthocytes), ceruloplasmin/copper (Wilson), thyroid function, ANA/antiphospholipid antibodies 3. If still undiagnosed: Gene panel for HD phenocopies (JPH3, TBP, ATN1, C9orf72, PRNP, VPS13A, XK, NKX2-1) 4. Consider: Brain MRI (caudate atrophy pattern), anti-neuronal antibodies
| Biomarker | Specimen | Clinical Utility |
|---|---|---|
| Mutant huntingtin (mHTT) | CSF | Pharmacodynamic marker for HTT-lowering therapies |
| Neurofilament light (NfL) | Plasma/CSF | Neurodegeneration marker; elevated in premanifest HD; tracks progression |
| GFAP | Plasma/CSF | Not a reliable early marker (PMID: 39891767) |
| Inflammatory cytokines | Plasma | IL-6, IL-8, TNF-α elevated; correlate with disease burden |
| Drug | Mechanism | Indication | Year Approved |
|---|---|---|---|
| Tetrabenazine (Xenazine) | VMAT2 inhibitor | Chorea | 2008 (FDA) |
| Deutetrabenazine (Austedo) | Deuterated VMAT2 inhibitor | Chorea | 2017 (FDA) |
| Valbenazine (Ingrezza) | Selective VMAT2 inhibitor | Chorea | 2023 (FDA) |
| Therapy | Type | Status | Notes |
|---|---|---|---|
| Tominersen | Non-selective ASO (intrathecal) | Phase III halted (2021) | Higher doses worsened outcomes; dose-dependent toxicity concerns |
| WVE-003 | Allele-selective ASO (SNP-targeting) | Phase I/II | Targets mHTT-linked SNP; spares wild-type HTT |
| AMT-130 | AAV5-delivered miRNA | Phase I/II | uniQure; one-time striatal injection; targets both HTT alleles |
| PTC518 | Oral splice modulator | Phase II | Promotes HTT exon skipping; oral bioavailability |
| Model | Type | CAG Length | Key Features |
|---|---|---|---|
| R6/2 | Transgenic (exon 1 fragment) | ~150 | Rapid progression; 12-16 week lifespan; robust phenotype |
| R6/1 | Transgenic (exon 1 fragment) | ~115 | Slower progression than R6/2 |
| YAC128 | Transgenic (full-length) | 128 | Full-length mHTT; striatal-specific neurodegeneration |
| BACHD | Transgenic (BAC, full-length) | 97 | Metabolic phenotype; slower progression |
| zQ175 | Knock-in | ~175 | Somatic expansion; closest to human genetics |
| HdhQ111 | Knock-in | 111 | Endogenous promoter; somatic instability |
| OVT73 sheep | Transgenic | 73 | Large animal model; closer to human brain size |
| HD minipig | Knock-in | ~124 | Large animal; long lifespan for longitudinal studies |
Recent evidence suggests mHTT affects brain development, with subtle abnormalities in cortical and striatal organization present from early life, years before clinical onset (PMID: 41252373). This challenges the traditional view of HD as purely a late-onset neurodegenerative disease.
The recognition that somatic CAG expansion in striatal neurons may be the rate-limiting step in disease onset has fundamentally shifted the therapeutic paradigm. The inherited CAG length sets the stage, but it is the ongoing somatic expansion that ultimately triggers neuronal death.
HD is increasingly recognized as a systemic disease, with pathology in skeletal muscle, heart, immune system, and endocrine organs, challenging the CNS-centric view.
NfL in plasma has emerged as a powerful, minimally invasive biomarker that can detect disease-related changes in premanifest HD carriers and may serve as a surrogate endpoint in clinical trials.
| Option | Description | Considerations |
|---|---|---|
| Natural conception | Accept 50% risk | Informed choice with genetic counseling |
| Prenatal testing | CVS at 10-12 wks or amniocentesis at 15-18 wks | Requires decision about potential termination |
| Exclusion testing | Tests linkage without revealing parent's status | Preserves parental autonomy; complex |
| PGT-M (PGD) | IVF with embryo selection | Avoids termination; costly; not universally available |
| Gamete donation | Donor egg/sperm from non-carrier | Eliminates genetic risk entirely |
| Adoption | Non-biological parenting | No genetic risk; availability varies |
Intermediate alleles represent a mutation-selection balance: new mutations continuously arise from the intermediate allele pool, maintaining HD in the population despite the reduced reproductive fitness of affected individuals. This also explains why HD prevalence is higher in populations (Western European) with larger proportions of high-normal/intermediate alleles.
Based on a Bayesian network meta-analysis (PMID: 41069601):
| Feature | Tetrabenazine | Deutetrabenazine | Valbenazine |
|---|---|---|---|
| FDA Approval | 2008 | 2017 | 2023 |
| Dosing | TID (3x/day) | BID (2x/day) | QD (1x/day) |
| CYP2D6 metabolism | Significant interaction | Reduced | Minimal |
| Chorea reduction (UHDRS-TMS) | ~5 points | ~4.4 points | ~3.2 points |
| Sedation/fatigue | Common (>30%) | Less common | Less common |
| Depression risk | Boxed warning | Lower risk | Lower risk |
| Key advantage | Most clinical experience | Better tolerability | Once daily; sprinkle formulation |
| Formulations | Tablets | Tablets | Capsules + sprinkle (PMID: 41215526) |
Clinical Pearl: All three VMAT2 inhibitors are symptomatic only (reduce chorea severity); none modify disease progression. Treatment choice should be individualized based on patient comorbidities, polypharmacy, and tolerance.
The Phase III GENERATION-HD1 trial of tominersen (Roche/Ionis) — a non-selective antisense oligonucleotide targeting both mutant and wild-type HTT via intrathecal delivery — was halted in March 2021 after an independent monitoring committee found that higher doses worsened clinical outcomes compared to placebo. Key lessons:
Post-tominersen, the field has shifted toward: - Allele-selective ASOs (WVE-003): Target mHTT-linked SNPs to lower only mutant HTT, preserving wild-type function - One-time gene therapy (AMT-130): AAV-delivered miRNA for sustained local HTT lowering in the striatum - Oral small molecules (PTC518): Splice modulators offering non-invasive, titratable dosing - Somatic expansion inhibitors: An entirely different approach that doesn't require HTT protein lowering — targets the upstream DNA instability mechanism - Combination strategies: Multiple complementary mechanisms may ultimately be needed
| Platform | Description | Scale |
|---|---|---|
| ENROLL-HD | Global observational study; natural history data | >20,000 participants, 20+ countries |
| HDSA Centers of Excellence | Specialized multidisciplinary HD clinics | 50+ centers in the US |
| EHDN | European HD clinical research network | Pan-European coordination |
| CHDI Foundation | Private foundation dedicated to HD drug discovery | >$100M/year funding |
| HD Clarity | Multi-site CSF biomarker collection | Global CSF repository |
| HDClarity | Biofluid collection for biomarker research | Standardized protocols |
| HDYO | HD Youth Organization | Youth-specific resources and support |
HD occupies a uniquely favorable position among neurodegenerative diseases for therapeutic development:
| Direction | Timeline | Potential Impact |
|---|---|---|
| Somatic expansion inhibitors (MSH3) | 2-5 years to clinical trials | Transformative — addresses root cause |
| Allele-selective ASOs | 3-5 years (Phase II/III data) | High — preserves wild-type HTT |
| Gene therapy (AAV) | 3-7 years (Phase II/III) | High — one-time treatment potential |
| Combination therapies | 5-10 years | Highest — multi-mechanism targeting |
| Precision medicine | 5-10 years | Moderate — CAG + modifier genotyping |
| Digital biomarkers | 1-3 years (adoption) | Moderate — continuous monitoring |
| Cell replacement therapy | 10+ years | Uncertain — circuit replacement challenge |
| Prevention trials in premanifest carriers | 5-10 years | Very high — prevent neurodegeneration |
Report compiled: April 2026 | Based on 69+ literature sources, Wikidata SPARQL queries, and domain knowledge 13 confirmed findings recorded in knowledge graph across 5 iterations